Grigg Ingeham and Liu Hanyang bank to develop new drugs for the treatment of NASH and liver disease
-
Last Update: 2021-02-16
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
today, Boehringer Ingelheim and Yuhan, a South Korean pharmaceutical company, jointly announced a partnership and licensing agreement.
The two companies will work together to develop innovative double agitations for the treatment of non-alcoholic fatty hepatitis (NASH) and related liver diseases, which bring together GLP-1 and FGF21 activity in a molecule.This collaboration combines Liu Hanyang's expertise in FGF21 biology, obesity and NASH with Bollinger Ingham's pharmaceutical expertise to deliver innovative drugs to patients with cardiometabolic disease.Preclinical evidence suggests that the efficacy of the gut hormone GLP-1 was more pronounced when combined with FGF21. The double agitation (GLP1R/FGF21R astration) is expected to reduce liver cell damage and liver inflammation by eliminating fatty hepatitis and direct antifibrosis.This in-house therapy could become a potential "first-in-class" therapy, further enriching Bronger Ingham's research and development pipeline for the treatment of NASH.YoKO has been a selected partner for cardiovascular and metabolic products at Bollinger Ingham for many years. Under the terms of the agreement, YoKO will receive $40 million in advance and up-to-date payments, and will be eligible for potential milestone payments of up to $830 million, as well as a share of future sales. (Drug Information Network)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
